July 08, 2024
2 min watch
We had been unable to course of your request. Please strive once more later. In the event you proceed to have this difficulty please contact customerservice@slackinc.com.
On this video, Alexander Chehrazi-Raffle, MD, discusses the outcomes of the CYCLONE 2 research into metastatic castration-resistant prostate most cancers, introduced at ASCO Annual Assembly.
Chehrazi-Raffle, a medical oncologist on the Metropolis of Hope Duarte Most cancers Heart, highlighted the research, which checked out a mixture remedy of abemaciclib (Verzenio, Eli Lilly & Co.) and abiraterone in a pattern of sufferers.
“We’ll have to attend for CYCLONE 3 to see if this mix has any worth within the high-risk, hormone-sensitive setting. However given the outcomes of CYCLONE 2, I do not anticipate there will be new alerts of efficacy,” Chehrazi-Raffle mentioned.
Revealed by:
We had been unable to course of your request. Please strive once more later. In the event you proceed to have this difficulty please contact customerservice@slackinc.com.
